Aiming to overcome technical and funding barriers in antibiotic development and ensuring a sustainable pipeline of new antibiotics to fight superbugs.
Portfolio 11
| Date | Name | Website | Total Raised | Location |
| 16.10.2025 | Peptilogic... | peptilogics.com | $118.9M | United Sta... |
| - | BioVersys ... | bioversys.com | $164.89M | Switzerlan... |
| - | Just a mom... | eliontx.com | - | - |
| - | BiomX Inc | biomx.com | $56M | Israel, Ce... |
| - | ANTABIO | antabio.com | $63.53M | France, Oc... |
| - | TenNor The... | tennorx.com | - | China, Gan... |
| - | Vedanta Bi... | vedantabio.com | $273.9M | United Sta... |
| - | F2G | f2g.com | $291M | United Kin... |
| - | Pattern Bi... | pattern.bio | $51M | United Sta... |
| - | UTILITY Th... | utilitytherapeutics.com | - | United Kin... |
Show more
Mentions in press and media 17
| Date | Title | Description |
| 18.10.2025 | Peptilogics Secures $78M to Advance Breakthrough PJI Therapy Zaloganan | Peptilogics, a clinical-stage biotechnology firm, closed an oversubscribed $78 million Series B2 funding round. This capital propels zaloganan (PLG0206), its lead candidate, toward a pivotal Phase 2/3 clinical trial. Zaloganan targets prost... |
| 16.10.2025 | Peptilogics: $78 Million Raised For Advancing Zaloganan Toward Pivotal Trial For Prosthetic Joint Infections | Peptilogics, a clinical-stage biotechnology company pioneering surgical therapeutics for medical device infections, has closed an oversubscribed $78 million Series B2 financing round. The funding round was led by Presight Capital, Thiel Bio... |
| 16.10.2025 | Peptilogics Raises $78M in Series B2 Funding | Peptilogics, a Pittsburgh, PA-based clinical-stage biotechnology company developing surgical therapeutics to effectively treat and prevent serious medical device infections, closed a $78m Series B2 financing round. Presight Capital, Thiel B... |
| 29.01.2025 | BioVersys to go public next week | BioVersys AG, a multi-asset, clinical stage biopharmaceutical company focusing on research and development of novel antibacterial products for serious life-threatening infections caused by multidrug-resistant (MDR) bacteria, announced toda... |
| 29.01.2025 | BioVersys sets IPO price at CHF 36.00 per share ahead of SIX Swiss Exchange debut | "As a scientific founder, the educational programs organized and co-organized by Venturelab, such as the SIX IPO Academy, provide very valuable toolboxes that you need during your entrepreneurial path," Marc Gitzinger, Co-Founder ... |
| 21.01.2025 | BioVersys to go public at SIX Swiss Exchange | BioVersys’ two clinical programs address life-threatening antibiotic resistant bacterial infections, focusing on profitable indications within the antibiotic space, in pneumonia, blood stream infections and meningitis. BioVersys’ two clini... |
| 24.09.2024 | Health | Drug-resistant germs will kill millions more people in coming decades, researchers warn | It was released in advance of a United Nations General Assembly meeting later this month on drug-resistant pathogens. “The numbers in the Lancet paper represent a staggering and unacceptable level of human suffering,” said Henry Skinner, ch... |
| 18.05.2024 | Health | A mother’s loss launches a global effort to fight antibiotic resistance | “Diary Of A Dying Girl” excerpts Mallory Smith’s own writings, which chronicle her 13-year battle against an antibiotic-resistant lung infection. (Genaro Molina/Los Angeles Times/TNS) On Tuesday, Random House published “Diary of a Dying Gir... |
| 06.01.2023 | Boston's Action Fund for antimicrobial resistance has closed its first European deal, pouring funds into Swiss biotech BioVersys | AMR Action Fund, a bacterial resistance-themed investment vehicle armed with $1 billion to spend, has backed a series C round for BioVersys, a developer of antimicrobial products based out of Basel, Switzerland. BioVersys's series C has now... |
| 05.01.2023 | AMR Action Fund Announces Investment in BioVersys AG | Deal marks Fund's first investment in Europe and advances its mission of enabling the launch of two to four antimicrobials by 2030 BOSTON, Jan. 5, 2023 /PRNewswire/ -- The AMR Action Fund, the world's largest public-private partnership inve... |
Show more